Clinical Trial Update: Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma [Phase 1]

View source ↗

Summary

This clinical trial update notes the completion of a Phase 1 study of ISB 1342, a CD38/CD3 bispecific antibody, in subjects with relapsed/refractory multiple my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ISB 1342

Snippet

Sponsor: Ichnos Sciences SA | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1 | Status: COMPLETED